Patents Assigned to UNIVERSITE COTE D'AZUR
  • Methods for determining the metabolic status of lymphomas
    Patent number: 10947598
    Abstract: Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 16, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Université Côte d'Azur, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Ehrland Ricci, Johanna Chiche, Catherine Thieblemont
  • HEPTANE FROM A PLANT SOURCE, FOR THE EXTRACTION OF NATURAL PRODUCTS
    Publication number: 20210024441
    Abstract: The present description relates to heptane obtained from a plant source, wherein the plant source comprises Commiphora wildii. Uses of said heptane in perfumery, cosmetics and food flavoring are also described.
    Type: Application
    Filed: January 29, 2019
    Publication date: January 28, 2021
    Applicants: UNIVERSITÉ CÔTE D'AZUR, Centre National de la Recherche Scientifique
    Inventors: Anne-Sophie Bouville, Cyrielle Dieffoldo, Xavier Fernandez, Stéphane Piquart
  • SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
    Publication number: 20210009657
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Sante et de la Recherche Medicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • New Uses of Lipophenolic Compounds
    Publication number: 20200360334
    Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.
    Type: Application
    Filed: November 12, 2018
    Publication date: November 19, 2020
    Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Superieure de Chimie, Institut de Recherche Pour le Developpement (IRD), Universite D'Aix-Marseille, Communaute Universites et Etablissements Universite Cote D Azur
    Inventors: Céline Crauste, Joseph Vercauteren, Fransisco Veas, Thierry Durand, Nicolas Blondeau
  • TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES
    Publication number: 20200297799
    Abstract: The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 24, 2020
    Applicants: Pfizer Inc., Université Côte d'Azur, INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique
    Inventors: Elvire Gouze, Stéphanie Garcia